[go: up one dir, main page]

SG11202007130RA - Methods and compositions for treatment of angiogenic disorders using anti-vegf agents - Google Patents

Methods and compositions for treatment of angiogenic disorders using anti-vegf agents

Info

Publication number
SG11202007130RA
SG11202007130RA SG11202007130RA SG11202007130RA SG11202007130RA SG 11202007130R A SG11202007130R A SG 11202007130RA SG 11202007130R A SG11202007130R A SG 11202007130RA SG 11202007130R A SG11202007130R A SG 11202007130RA SG 11202007130R A SG11202007130R A SG 11202007130RA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
methods
angiogenic disorders
vegf agents
Prior art date
Application number
SG11202007130RA
Inventor
Napoleone Ferrara
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67395742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202007130R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of SG11202007130RA publication Critical patent/SG11202007130RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202007130RA 2018-01-26 2019-01-25 Methods and compositions for treatment of angiogenic disorders using anti-vegf agents SG11202007130RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862622382P 2018-01-26 2018-01-26
PCT/US2019/015160 WO2019147944A1 (en) 2018-01-26 2019-01-25 Methods and compositions for treatment of angiogenic disordres using anti-vegf agents

Publications (1)

Publication Number Publication Date
SG11202007130RA true SG11202007130RA (en) 2020-08-28

Family

ID=67395742

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007130RA SG11202007130RA (en) 2018-01-26 2019-01-25 Methods and compositions for treatment of angiogenic disorders using anti-vegf agents

Country Status (17)

Country Link
US (2) US11524053B2 (en)
EP (2) EP3743091B1 (en)
JP (2) JP7517988B2 (en)
KR (1) KR20200112893A (en)
CN (2) CN116059318A (en)
AU (2) AU2019212622B2 (en)
BR (1) BR112020015074A2 (en)
CA (1) CA3089481A1 (en)
CO (1) CO2020010384A2 (en)
DK (1) DK3743091T3 (en)
EA (1) EA202091786A1 (en)
ES (1) ES3009668T3 (en)
FI (1) FI3743091T3 (en)
IL (2) IL276158B2 (en)
MX (1) MX2021001424A (en)
SG (1) SG11202007130RA (en)
WO (1) WO2019147944A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. Antibodies and conjugates thereof
CA3089481A1 (en) 2018-01-26 2019-08-01 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
BR112020022610A2 (en) 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. high concentration vegf receptor fusion protein containing formulations
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023502501A (en) * 2019-11-25 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Long-acting VEGF inhibitors for intraocular angiogenesis
CN114652826B (en) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 Use of anti-EGFR antibodies
CN117304307A (en) * 2022-06-27 2023-12-29 上海鼎新基因科技有限公司 AAV medicine for treating neovascular related fundus diseases
CN117535299B (en) * 2023-10-27 2024-12-06 北京生物制品研究所有限责任公司 Isolated nucleic acid molecule, recombinant virus or use thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
DE69434115T2 (en) 1993-03-25 2005-10-27 Merck & Co., Inc. INHIBITOR OF THE GROWTH FACTOR FOR VITAL TREATMENT CELLS
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
JPH09154588A (en) 1995-10-07 1997-06-17 Toagosei Co Ltd Vegf-binding polypeptide
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP3011144B2 (en) 1997-07-31 2000-02-21 日本電気株式会社 Optical scanner and its driving method
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
MEP3208A (en) 1999-06-08 2010-02-10 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
CA2373237A1 (en) 2000-03-10 2001-09-20 Insite Vision Incorporated Methods and compositions for treating and preventing posterior segment ophthalmic disorders
JP2006527198A (en) 2003-06-06 2006-11-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Tumor regression method using VEGF inhibitor
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (en) 2003-07-25 2005-12-14 Regeneron Pharma COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT
EP1696949A4 (en) 2003-11-10 2008-02-06 Ghc Res Dev Corp Vegf receptor antagonists
US7354580B2 (en) 2004-06-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
US20080292628A1 (en) * 2004-10-12 2008-11-27 Amprotein Corporation Chimeric Protein
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
EP1853298A2 (en) 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CN101160123B (en) 2005-02-18 2013-07-17 阿布拉科斯生物科学有限公司 Combinations of therapeutic agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
PL1861116T3 (en) 2005-03-25 2016-02-29 Regeneron Pharma Vegf antagonist formulations
AU2006279658A1 (en) 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a VEGF antagonist
CA2619048A1 (en) 2005-08-15 2007-02-22 The Regents Of The University Of California Vegf-activated fas ligands
CN100471872C (en) 2005-11-04 2009-03-25 余波 Optimizing fusion protein containing VEGF recerver segment and medical application thereof
DK1962895T3 (en) 2005-12-16 2013-03-04 Regeneron Pharma THERAPEUTIC USE OF A Dll4 ANTAGONIST AND A VEGF INHIBITOR TO TUMOR GROWTH
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
UA100969C2 (en) 2006-03-21 2013-02-25 Дженентек, Інк. Combinatorial therapy involving alpha5beta1 antagonists
PT2364691E (en) 2006-06-16 2013-05-15 Regeneron Pharma Vegf antagonist formulations suitable for intravitreal administration
WO2008073509A2 (en) 2006-12-11 2008-06-19 Genentech, Inc. Compositions and methods for treating a neoplasm
CL2008002782A1 (en) 2007-09-21 2009-07-31 Genentech Inc Neutralizing anti-bv8 antibody; composition comprising it; and its use to treat tumors in humans previously treated with a vascular endothelial growth factor antagonist.
CN102317320A (en) * 2008-12-11 2012-01-11 韩国科学技术院 Fusion proteins capable of binding to VEGF-A and TNF-alpha
CN101838329A (en) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 Anti-angiogenesis fusion protein
KR101248912B1 (en) * 2009-12-31 2013-03-29 한양대학교 산학협력단 Recombinant Adenovirus Having Anti―Angiogenesis Activity
PL2601214T3 (en) 2010-08-06 2018-05-30 Genzyme Corporation Vegf antagonist compositions and uses thereof
CN103533950A (en) 2011-01-13 2014-01-22 瑞泽恩制药公司 Use of a vegf antagonist to treat angiogenic eye disorders
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CA2862835A1 (en) 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
WO2013152351A2 (en) 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
MX373894B (en) 2012-11-08 2020-07-09 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
WO2014160507A1 (en) 2013-03-13 2014-10-02 Genzyme Corporation Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof
WO2015000181A1 (en) * 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 Novel recombinant fusion protein, preparation method therefor and use thereof
ES2950987T3 (en) 2013-09-11 2023-10-17 Neurotech Usa Inc Cartridge for encapsulated cell therapy
US9657084B2 (en) 2014-01-25 2017-05-23 Chengdu Kanghong Biotechnologies Co., Ltd. Fusion protein inhibiting angiogenesis or growth and use thereof
KR101819135B1 (en) 2014-03-18 2018-01-18 한국과학기술원 Glycosylated VEGF Decoy Receptor Fusion Protein
RU2702748C2 (en) 2014-05-12 2019-10-11 Формикон Аг Pre-filled plastic syringe containing vegf antagonist
WO2016044041A1 (en) 2014-09-16 2016-03-24 Regeneron Pharmaceuticals, Inc. Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
MX377593B (en) 2014-11-07 2025-03-10 Ai Therapeutics Inc Apilimod for use in the treatment of renal cancer
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
US10342669B2 (en) 2015-04-07 2019-07-09 Zimmer, Inc. Convertible glenoid
CN108430489B (en) 2015-06-28 2022-03-25 新源生物科技股份有限公司 Fusion proteins for inhibiting angiogenesis
MX2018006171A (en) 2015-11-18 2018-12-19 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist.
KR101685532B1 (en) 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
EP3412288A1 (en) 2017-06-08 2018-12-12 Galderma Research & Development Vegf inhibitors for use for preventing and/or treating acne
CA3068635A1 (en) 2017-06-30 2019-01-03 Korea Advanced Institute Of Science And Technology Conjugate of vegf-grab protein and drug, and use thereof
US20200255496A1 (en) 2017-09-18 2020-08-13 Amgen Inc. Vegfr-fc fusion protein formulations
CN109575140B (en) 2017-09-29 2021-02-23 北京比洋生物技术有限公司 Dual-targeting fusion proteins targeting PD-1 or PD-L1 and targeting the VEGF family and uses thereof
EP3709971A2 (en) 2017-11-17 2020-09-23 Amgen Inc. Vegfr-fc fusion protein formulations
CA3089481A1 (en) 2018-01-26 2019-08-01 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
KR20200119274A (en) 2018-02-06 2020-10-19 에프. 호프만-라 로슈 아게 Treatment of eye diseases
JP2023502501A (en) 2019-11-25 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Long-acting VEGF inhibitors for intraocular angiogenesis

Also Published As

Publication number Publication date
AU2024204947A1 (en) 2024-08-08
US20200353041A1 (en) 2020-11-12
EP3743091B1 (en) 2024-11-06
EP3743091A4 (en) 2021-12-15
CN111741761A (en) 2020-10-02
IL276158B2 (en) 2024-07-01
BR112020015074A2 (en) 2020-12-08
EP4495136A2 (en) 2025-01-22
ES3009668T3 (en) 2025-03-31
US11524053B2 (en) 2022-12-13
US20240366721A1 (en) 2024-11-07
AU2019212622B2 (en) 2024-05-23
IL276158A (en) 2020-09-30
WO2019147944A1 (en) 2019-08-01
AU2019212622A1 (en) 2020-08-13
EA202091786A1 (en) 2020-10-20
JP7517988B2 (en) 2024-07-17
KR20200112893A (en) 2020-10-05
JP2024149493A (en) 2024-10-18
CN116059318A (en) 2023-05-05
DK3743091T3 (en) 2025-01-06
EP3743091A1 (en) 2020-12-02
CN111741761B (en) 2023-04-18
IL310376A (en) 2024-03-01
IL276158B1 (en) 2024-03-01
JP2021511061A (en) 2021-05-06
FI3743091T3 (en) 2025-01-03
WO2019147944A8 (en) 2020-08-20
CA3089481A1 (en) 2019-08-01
CO2020010384A2 (en) 2020-12-10
MX2021001424A (en) 2021-06-23

Similar Documents

Publication Publication Date Title
IL276158A (en) Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
IL269378A (en) Optimized antibody compositions for treatment of ocular disorders
IL298690B1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
ZA202002066B (en) Compositions and methods for the treatment of eye disorders
IL286636A (en) Compositions and methods for the treatment of kras associated diseases or disorders
IL273960A (en) Compositions for and method of treating acid-base disorders
SG11202103033WA (en) Compositions and methods for the treatment of presbyopia
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
IL272937A (en) Compositions and methods for the treatment of fibrotic diseases
IL275985A (en) Compositions and methods for treating retinal disorders
SG11202104053TA (en) Compositions and methods for the treatment of estrogen-dependent disorders
EP3897641C0 (en) Treatment of movement disorders
IL287594A (en) Compositions and methods for the treatment of retinal degeneration
IL292186A (en) Compositions and methods for treating blood disorders
IL287831A (en) Oxymetazoline compositions and methods for treating ocular disorders
IL278978A (en) Compositions and methods for treatment of psoriasis
EP4010347A4 (en) Compositions and methods for the treatment of pain and dependance disorders
IL276669A (en) Composition for prevention and treatment of hair growth disorders
SG11202012473UA (en) Ophthalmic compositions and methods for the treatment of eye disorders
IL282739A (en) Compositions and methods for the treatment of smooth muscle dysfunction
IL291184A (en) Compositions and methods for treatment of disorders associated with clec16a dysfunction or loss
GB201810925D0 (en) Compositions and methods of treatment